BNTX Stock Recent News

CureVac said on Thursday that the company and GSK have entered an agreement to a resolve patent dispute with Pfizer and BioNTech related to mRNA-based COVID-19 vaccines.

BioNTech SE BNTX reported a narrower loss for the second quarter on Monday.

BioNTech SE (NASDAQ:BNTX ) Q2 2025 Earnings Conference Call August 4, 2025 8:00 AM ET Company Participants Douglas Maffei - Investor Relations Ozlem Tureci - Co-Founder, Chief Medical Officer & Member of Management Board Ramón Zapata-Gomez - CFO & Member of Management Board Ryan Richardson - Chief Strategy Officer, MD & Member of Management Board Ugur Sahin - Co-Founder, CEO & Chair of the Management Board Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Asad Haider - Goldman Sachs Group, Inc., Research Division Cory William Kasimov - Evercore Inc. Daina Michelle Graybosch - Leerink Partners LLC, Research Division Jessica Macomber Fye - JPMorgan Chase & Co, Research Division Tazeen Ahmad - BofA Securities, Research Division Terence C. Flynn - Morgan Stanley, Research Division Operator Welcome to BioNTech Second Quarter 2025 Earnings Call.

BioNTech SE  BNTX reported a second-quarter per-share loss of $1.82 (1.60 euros) on Monday, up from a loss of 3.36 euros reported a year ago, compared to beating the consensus loss of $2.42 per share.

The drug maker reported a narrower-than-expected loss in the second quarter.

German biotech firm BioNTech on Monday said that second-quarter revenues more than doubled to 261 million euros ($302 million), driven by higher revenues from its COVID-19 vaccine collaboration with Pfizer.

Continued execution of BioNTech's oncology strategy with focus on two pan-tumor programs including two announced transactions: mRNA-based cancer immunotherapy candidates and BNT327, a bispecific antibody candidate targeting PD-L1 1 and VEGF-A Entered a global strategic co-development and co-commercialization collaboration with Bristol Myers Squibb (“BMS”) to jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types Announced strategic transaction to acquire CureVac N.V. (“CureVac”) to strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates Presented multiple clinical updates across diversified oncology pipeline at medical meetings validating the Company's oncology combination strategy Approval received for new variant-adapted COVID-19 vaccine by the European Commission (“EC”); further launch preparation underway as recommended by regulators, with deliv

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal.

Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing globally, the future of gene therapy, changes at FDA, and more.

CNBC's Joe Kernen reports on the latest news.